Compugen (CGEN) Free Cash Flow (2009 - 2010)
Compugen (CGEN) reported Free Cash Flow of -$919000.0 for Q4 2010, up 57.28% on a YoY basis from -$584324.3 in Q4 2009, and down 141.84% sequentially from -$380000.0 in Q3 2010.
Compugen (CGEN) Free Cash Flow (2009 - 2010) Analysis & Trends
Compugen (CGEN) has 2 years of Free Cash Flow data on file, last reported at -$919000.0 in Q4 2010.
- For the quarter ending Q4 2010, Free Cash Flow rose 57.28% year-over-year to -$919000.0; the trailing twelve-month figure through Sep 2011 stood at -$919000.0 (up 63.69% YoY), and the FY2025 full-year result was $31.3 million, down 36.69% from the prior year.
- Free Cash Flow slipped to -$919000.0 in Q4 2010, from -$380000.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$380000.0 in Q3 2010 to a low of -$2.2 million in Q4 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Compugen | 221.26 Mn | 129.51 Mn | 352,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | -919,000.00 |
| Dec 31, 2010 | -919,000.00 |
| Sep 30, 2010 | -380,000.00 |
| Sep 30, 2010 | -380,000.00 |
| Dec 31, 2009 | -2.15 Mn |
| Dec 31, 2009 | -2.15 Mn |
| Sep 30, 2009 | -942,000.00 |
| Sep 30, 2009 | -942,000.00 |